In 2023 the FDA placed CJC-1295 in "Category 2" of its interim 503A bulks list, meaning it identified significant safety concerns and did not permit its use in traditional pharmacy compounding
3mg/kg/day for 10 days, 2mg/kg/day for 10 days and then 1mg/kg/day for 10 days)
These insights should be combined with biomarker data and clinical evaluation to guide dosing conversations with your provider
Preventive Services Task Force reached the same conclusion: Limited evidence supports any benefit of supplementation for prevention of cardiovascular disease or cancer [PMID: 24366536]
Most patients experience visible changes in their body composition after about 2-3 months of consistent use
Accelerated Tissue Repair BPC-157 significantly supports the fast repair of various tissues, including muscles, tendons, ligaments, and even bone